Shuji Kinoshita

Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

Yoshinobu Nakamaru, Yoshiharu Hayashi, Ruriko Ikegawa et al. · Xenobiotica · 2013 · 56 citations

Tolerability, pharmacokinetics and pharmacodynamics of <scp>TA</scp>‐8995, a selective cholesteryl ester transfer protein (<scp>CETP</scp>) inhibitor, in healthy subjects

J. Ford, Matt Lawson, D. E. Fowler et al. · British Journal of Clinical Pharmacology · 2014 · 49 citations · Full text

Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-α and macrophage inflammatory protein-2 production

Kaoru Ishizaki, Tomomichi Iwaki, Shuji Kinoshita et al. · European Journal of Pharmacology · 2007 · 38 citations

Inflammation, Hepatology, Medicine +11

Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers

Shuji Kinoshita, Kazuoki Kondo · Expert Opinion on Drug Metabolism & Toxicology · 2014 · 26 citations

Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations

Yoshinobu Nakamaru, Shuji Kinoshita, Atsuhiro Kawaguchi et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2017 · 23 citations · Full text